Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | TMPRSS4 | Q9NRS4 | 3/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.43 |
| ▸ | ATF1 | P18846 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.42 |
| ▸ | PTGES | O14684 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.42 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | RUVBL1 | Q9Y265 | 1/20 | 0.42 |
| ▸ | JUN | P05412 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14083341 | 0.89 | RXFP1 (0.64) | RXFP1TRPV1MAPT | |
| SCHEMBL14083217 | 0.89 | TMPRSS4 (0.52) | TMPRSS4TRPV1NFKB1ATF1EGLN1 | |
| SCHEMBL14083327 | 0.89 | TRPV1 (0.61) | RXFP1TRPV1EGLN1 | |
| SCHEMBL14083170 | 0.89 | RXFP1 (0.47) | RXFP1TMPRSS4TRPV1NFKB1ATF1 | |
| SCHEMBL14083322 | 0.87 | GRM4 (0.49) | RXFP1MAPT | |
| SCHEMBL14083607 | 0.86 | TRPV1 (0.58) | TMPRSS4TRPV1NFKB1ATF1EGLN1 | |
| SCHEMBL14083361 | 0.85 | TRPV1 (0.58) | TMPRSS4TRPV1NFKB1ATF1EGLN1 | |
| SCHEMBL14083342 | 0.84 | TRPV1 (0.51) | RXFP1TRPV1MAPT | |
| SCHEMBL14083329 | 0.84 | TRPV1 (0.51) | RXFP1TRPV1PTGESMAPT | |
| SCHEMBL14083344 | 0.84 | TRPV1 (0.49) | RXFP1TRPV1PTGESMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | KELLY MICHAEL G | 2008-08-21 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338950-B2 | Amide compounds as ion channel ligands and uses thereof | RENOVIS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200524-A1 | Amide compounds as ion channel ligands and uses thereof | TRPV1, TRPA1, TRPV2 | RXFP1 1053/4885TMPRSS4 1826/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.